CRSP · CRISPR Therapeutics AG
$59.50
+1.38 (+2.37%)
At close · Aug 21
Market Cap
$5.75B
Shares
96.69M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$3.51M
-90.6%
FY2025
Net Income
-$581.6M
-58.8%
FY2025
Operating Margin
-18933.65%
-17683.3pp
FY2025
Diluted EPS
-$6.47
-49.1%
FY2025
Operating Cash Flow
-$345.01M
-141.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $13.39M | $3.51M | $37.31M | $371.21M | $1.2M | $914.96M | $719K | $289.59M | $3.12M | $41M | $5.16M | $247K | — | |
| $278.15M | $284.81M | $310.24M | $387.33M | $461.65M | $340.57M | $221.38M | $179.36M | $113.77M | $69.8M | $42.24M | $12.57M | $1.51M | |
| $70.07M | $73.54M | $72.98M | $76.16M | $102.46M | $99.69M | $85.75M | $63.49M | $48.29M | $35.85M | $31.06M | $13.4M | $5.11M | |
| — | $19.48M | $19.26M | $19.84M | $24.17M | $17.95M | $9.18M | $4.73M | $3.52M | $3.02M | $925K | $127K | $38K | |
| $547.73M | $668.08M | $503.88M | $593.74M | $674.36M | $541.44M | $355.15M | $242.85M | $162.07M | $105.65M | $73.29M | $25.98M | $6.63M | |
| -$534.34M | -$664.57M | -$466.57M | -$222.54M | -$673.16M | $373.53M | -$354.44M | $46.74M | -$158.94M | -$64.65M | -$68.13M | -$25.73M | -$6.63M | |
| — | -18933.65% | -1250.38% | -59.95% | -56190.4% | 40.82% | -49295.55% | 16.14% | -5087.8% | -157.69% | -1319.33% | -10416.6% | — | |
| — | -$645.09M | -$447.31M | -$202.7M | -$648.99M | $391.48M | -$345.25M | $51.47M | -$155.42M | -$61.62M | -$67.21M | -$25.6M | -$6.59M | |
| — | — | $104.3M | $76.4M | $23.3M | — | — | — | — | — | — | — | — | |
| $86.23M | $86.61M | $103.9M | $71.82M | $22.66M | $6M | $6.38M | $20.57M | -$5.49M | -$1.96M | $45.41M | -$92K | -$236K | |
| — | — | — | — | — | — | — | -$5.47M | -$4.28M | -$1.76M | -$36.5M | — | — | |
| -$448.11M | -$577.97M | -$362.67M | -$150.72M | -$650.5M | $379.53M | -$348.06M | $67.31M | -$164.43M | -$66.61M | -$22.72M | -$25.82M | -$6.86M | |
| $3.03M | $3.63M | $3.59M | $2.89M | -$325K | $1.87M | $809K | $448K | $553K | $1.75M | $484K | $7000 | -$63K | |
| -$451.14M | -$581.6M | -$366.25M | -$153.61M | -$650.18M | $377.66M | -$348.87M | $66.86M | -$164.98M | -$68.36M | -$23.18M | -$25.5M | -$7.01M | |
| — | -16569.77% | -981.54% | -41.38% | -54271.7% | 41.28% | -48520.86% | 23.09% | -5281.08% | -166.74% | -448.82% | -10325.1% | — | |
| — | — | — | — | — | — | — | — | — | — | -$25K | -$325K | -$536K | |
| — | — | — | — | — | — | — | $66.86M | -$164.98M | -$68.36M | — | — | — | |
| -$459.81M | -$578.62M | -$366.33M | -$136.05M | -$660.76M | $372.68M | -$348.96M | $66.87M | -$165M | -$68.32M | -$23.22M | -$25.83M | -$6.8M | |
| USD/shares | — | -$6.47 | -$4.34 | -$1.94 | -$8.36 | $4.97 | -$5.29 | $1.23 | -$3.44 | -$1.71 | — | — | — |
| USD/shares | — | -$6.47 | -$4.34 | -$1.94 | -$8.36 | $4.70 | -$5.29 | $1.17 | -$3.44 | -$1.71 | — | — | — |
| shares | — | 89.93M | 84.36M | 79.22M | 77.75M | 75.95M | 65.95M | 54.39M | 47.96M | 40.06M | 12.26M | 5.04M | 3.56M |
| shares | — | 89.93M | 84.36M | 79.22M | 77.75M | 80.39M | 65.95M | 56.93M | 47.96M | 40.06M | 12.26M | 5.04M | 3.56M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
296.82×
Peer median 7.95×
EV/EBIT
—
Peer median 29.15×
P/E (TTM)
—
Peer median 19.00×
Peer medians compare against the 189 similar-size Biotechnology companies (of 546 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Grant | $3,510,000 | $2,314,000 | $1,206,000 | $762,000 | $1,882,000 | $176,000 | — | — |
| Collaboration Revenue | $0 | $35,000,000 | $370,000,000 | $436,000 | $913,081,000 | $543,000 | $289,590,000 | $3,124,000 |
Key facts
CIK
1674416
CUSIP
H17182108
13F (30d)
429 filings
417 filers
Visit website
Investor relations